ホーム › 非小細胞肺癌 › ミズーリ州 › Kansas City
Kansas City、MOにおける非小細胞肺癌の臨床試験
Kansas Cityとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する31件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- St. Lukes Hosp. of Kansas City /ID# 259940, Kansas City
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
被験者募集中第3相
- Truman Medical Center ( Site 0126), Kansas City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Saint Luke's Hospital of Kansas City, Kansas City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- University Health Truman Medical Center, Kansas City
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- St. Lukes Hospital of Kansas City, Kansas City
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- The University of Kansas Cancer Center, Westwood · 5マイル先
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
被験者募集中第2相
- University of Kansas Cancer Center, Westwood · 5マイル先
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Truman Medical Ctr West, Kansas City
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Westwood · 5マイル先
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
被験者募集中第3相
- Saint Luke's Hospital of Kansas City, Kansas City
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Kansas City
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
被験者募集中第3相
- Local Institution - 0498, Kansas City
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, Kansas City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Kansas City
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
被験者募集中第1相
- University of Kansas, Westwood · 5マイル先
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2/3相
- University of Kansas Medical Center /ID# 263196, Westwood · 5マイル先
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- Saint Luke's Cancer Institute, Kansas City
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- The University of Kansas Cancer Center - Westwood, Westwood · 5マイル先
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- University of Kansas Cancer Center - North, Kansas City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- University of Kansas Medical Center (KUMC), Westwood · 5マイル先
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
被験者募集中第1相
- MidAmerica Cancer Care, Kansas City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- The University of Kansas Cancer Center - Westwood, Westwood · 5マイル先
- University of Kansas Cancer Center, Westwood · 5マイル先
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
被験者募集中第3相
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center, Westwood · 5マイル先
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
被験者募集中第1/2相
- The University of Kansas Cancer Center, Westwood · 5マイル先
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- 他1件
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Research Site, Kansas City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- 他1件
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- Kansas City Veterans Affairs Medical Center, Kansas City
- 他2件
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- 他1件
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- 他1件
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Kansas City
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Kansas Cityにおける他の研究
- 乳がん34件の研究
- 心不全25件の研究
- がん（全種類）21件の研究
- 肺がん19件の研究
- 大腸癌16件の研究
- 転移性癌15件の研究
- 急性骨髄性白血病15件の研究
- 前立腺がん14件の研究
- 卵巣がん11件の研究
- 肥満症11件の研究
- 2型糖尿病11件の研究
- 心血管疾患11件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。